Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 4-[[(3-chloro-4-(methoxy-13C-d3)phenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C22[13C]H23ClD3N7O3
Formula Weight: 488.0
CAS Number: 2738376-89-9
Notes: Avanafil-13C-d3 is intended for use as an internal standard for the quantification of avanafil (Item No. 23024) by GC- or LC-MS. Avanafil is an orally bioavailable inhibitor of phosphodiesterase 5 (PDE5; IC50 = 5.2 nM).{40239,40271} It is selective for PDE5 over PDE6, PDE1-4, and PDE7-11 (IC50s = 630, >5,000, and >5,000 nM, respectively).{40239} Avanafil (300 µg/kg, i.v.) potentiates pelvic nerve stimulation-induced penile tumescence in anesthetized dogs. Formulations containing avanafil have been used in the treatment of erectile dysfunction.
English
Deutsch
